Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 11:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 399 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Testosterone Clear all

Conditions: Menopause, Sexual Dysfunction, Libido Disorder, Testosterone Deficiency
Interventions: Transdermal testosterone gel, Transdermal placebo gel; Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy
Interventions: Testosterone gel, Dutasteride, Depo-Medroxyprogesterone (DMPA), Placebo Testosterone gel, Placebo dutasteride, Placebo DMPA; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 25 Years to 55 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Primary Ovarian Insufficiency, Female Infertility Due to Diminished Ovarian Reserve
Interventions: Testosterone cream (0.5mg per gram), DHEA, Placebo; Drug · Dietary Supplement
Lead sponsor: Center for Human Reproduction; Other
Eligibility: 38 Years to 44 Years · Female only
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 2
States / cities: New York, New York • Rochester, New York

Conditions: Hypoactive Sexual Desire Disorder
Interventions: Testosterone Transdermal System, Placebo patch; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Depression
Interventions: Testosterone, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 21 Years to 75 Years · Female only
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Boston, Massachusetts • Providence, Rhode Island

Conditions: Andropause
Interventions: AndroGel® (testosterone gel), Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 65 Years and older · Male only
Enrollment: 790 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2018
U.S. locations: 12
States / cities: Birmingham, Alabama • La Jolla, California • Torrance, California + 9 more

Conditions: Female Sexual Dysfunction
Interventions: Low dose testosterone nasal gel, single dose, Medium dose testosterone nasal gel, single dose, High dose testosterone nasal gel, single dose, Medium dose testosterone nasal gel, multiple dose; Drug
Lead sponsor: Acerus Pharmaceuticals Corporation; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Ejaculatory Dysfunction, Hypogonadism
Interventions: Testosterone Solution 2%, Placebo Solution; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 26 Years and older · Male only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 6
States / cities: Los Angeles, California • San Diego, California • New Orleans, Louisiana + 3 more

Conditions: Adult Male Hypogonadism
Interventions: Testosterone gel (FE 999303); Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 22
States / cities: Anniston, Alabama • Huntsville, Alabama • Newport Beach, California + 19 more

Conditions: Biochemically Recurrent Prostate Cancer
Interventions: Darolutamide(BAY1841788, Nubeqa), Enzalutamide; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 5
States / cities: Sherman Oaks, California • Boston, Massachusetts • New York, New York + 1 more

Conditions: Hypogonadotropic Hypogonadism
Interventions: BGS649; Drug
Lead sponsor: Mereo BioPharma; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 37
States / cities: Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 34 more

Conditions: Hypoactive Sexual Desire Disorder (HSDD)
Interventions: Testosterone Transdermal System, Placebo patch; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 549 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Aging
Interventions: Placebo, Testosterone; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 60 Years and older
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 2
States / cities: Galveston, Texas • Texas City, Texas

Conditions: Kidney Failure, Kidney Diseases
Interventions: Testim, 1% testosterone gel; Drug
Lead sponsor: Palo Alto Veterans Institute for Research; Other
Eligibility: 45 Years to 80 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Palo Alto, California • San Jose, California

Conditions: Healthy Aging
Interventions: Not listed
Lead sponsor: Innovus Pharmaceuticals, Inc.; Industry
Eligibility: 55 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: San Diego, California

Conditions: Major Depressive Disorder, Anxiety Disorders
Interventions: Hydrocortisone; Drug
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Austin, Texas

Conditions: Meibomian Gland Dysfunction
Interventions: testosterone ophthalmic solution, vehicle of testosterone ophthalmic solution; Drug
Lead sponsor: ORA, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Klinefelter Syndrome, 47,XXY, Sex Chromosome Aneuploidy, XXY Syndrome
Interventions: No intervention; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 12 Years to 17 Years · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions: Selinexor; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Secondary Hypogonadism
Interventions: Androxal, Placebo; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 23
States / cities: Mobile, Alabama • Little Rock, Arkansas • Garden Grove, California + 19 more

Conditions: Cancer of Prostate
Interventions: leuprolide acetate; Drug
Lead sponsor: San Bernardino Urological Associates Medical Group Inc; Other
Eligibility: 18 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: San Bernardino, California

Conditions: Hypogonadism, Atherosclerosis
Interventions: Testosterone Gel (Androgel), Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 60 Years and older · Male only
Enrollment: 308 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2012
U.S. locations: 3
States / cities: Phoenix, Arizona • Los Angeles, California • Boston, Massachusetts

Conditions: brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer
Interventions: therapeutic estradiol, deslorelin, therapeutic testosterone, therapeutic conventional surgery, active surveillance, quality-of-life assessment, laboratory biomarker analysis; Biological · Drug · Procedure + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 21 Years to 48 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2024
U.S. locations: 1
States / cities: Duarte, California

Conditions: Hypogonadism
Interventions: 10.0 mg of Testosterone, 4.0% TID, 13.5 mg of Testosterone, 4.5% B.I.D, 11.25 mg of Testosterone, 4.5% T.I.D; Drug
Lead sponsor: Acerus Pharmaceuticals Corporation; Industry
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 3
States / cities: Tucson, Arizona • Miami, Florida • Shreveport, Louisiana

Search by objective public record fields.

Transdermal Testosterone Gel for Female Sexual Interest and Arousal Disorder in Peri- and Post Menopause

PROS-1-Male Hormonal Contraceptive Regimens on Prostate Tissue

Effect of Testosterone Treatment on Embryo Quality

Study of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido

Testosterone Antidepressant Augmentation in Women

The Testosterone Trials in Older Men

PK Study of Testosterone Nasal Gel (TBS-2) in Healthy Premenopausal Women

A Study of Ejaculatory Dysfunction in Men With Low Testosterone Levels

A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel in Adult Hypogonadal Males

A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide

A 6 Month Safety Extension Study of MBGS205

Study to Assess the Efficacy/Safety of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido

Cycled Testosterone Therapy to Improve Physical Function in Frail Nursing Home Residents

Testosterone Replacement Therapy in Advanced Chronic Kidney Disease

An Open Label Study to Assess the Effect of Euryco-10® Oral Dietary Supplement in Senior Men

Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration

Safety and Efficacy Study of a Testosterone Eye Drop for the Treatment of Meibomian Gland Dysfunction

Cardiometabolic Profiles of Boys With Klinefelter Syndrome

Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer

Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism

A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer

Testosterone Replacement in Older Men and Atherosclerosis Progression

Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease

Efficacy of an Intranasal Testosterone Product